Safety Study of BMS-844421 for Treatment of Hypercholesterolemia

Randomized, Double-blind, Placebo-Controlled, Ascending Single- and Multiple-Dose Study to Evaluate the Safety , Pharmacokinetics and Pharmacodynamics of BMS-844421 in Healthy Subjects and in Subjects With Elevated Cholesterol

The purpose of this study is to assess the safety, tolerability, serum concentrations and pharmacodynamic effects on serum low-density lipoprotein (LDL) cholesterol of single and multiple subcutaneous and intravenous doses of BMS-844421 in healthy subjects (SAD) and in subjects with elevated cholesterol (MAD).

Inclusion Criteria:

• Healthy Subjects (SAD)
• Healthy Subjects (MAD) with untreated elevated cholesterol
• Body Mass Index (BMI) of 18 to 30 kg/m² inclusive
• Women who are not of childbearing potential and men, ages 18 to 45

Exclusion Criteria:

• Any significant acute or chronic medical illness
• History of liver or renal disorders
• Prior use of any prescription or over-the-counter lipid lowering drugs, within 8 weeks prior to study drug administration